{"schema_version":"secwatch.filing_event.v1","accession":"0001093557-25-000029","form_type":"8-K","ticker":"DXCM","cik":"0001093557","company_name":"DEXCOM INC","filed_at":"2025-02-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:02.909638+00:00","generated_at":"2026-05-26T21:59:09.135883+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Dexcom Q4 revenue $1.114B (+8% YoY); GAAP EPS $0.38; FY2025 guidance $4.6B","bullets":["Q4 revenue $1.114B (+8% YoY); U.S. +4%, international +17% reported.","GAAP net income $151.7M ($0.38 diluted EPS) vs $256.3M ($0.62) YoY; non-GAAP EPS $0.45 vs $0.50.","Full year 2024 revenue $4.033B (+11% YoY); GAAP operating margin 14.9% (-160bps); non-GAAP margin 18.8% (-100bps).","Submitted G7 15-day CGM to FDA; secured Dexcom ONE+ reimbursement in France; partnership with ŌURA.","FY2025 guidance: revenue $4.60B (+14% growth); non-GAAP gross margin ~64-65%; operating margin ~21%; Adj. EBITDA ~30%."],"urls":{"canonical":"https://secwatch.observer/filing/0001093557-25-000029","json":"https://secwatch.observer/filing/0001093557-25-000029.json","markdown":"https://secwatch.observer/filing/0001093557-25-000029.md","text":"https://secwatch.observer/filing/0001093557-25-000029.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1093557/000109355725000029/0001093557-25-000029-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1093557/000109355725000029/dxcm-20250213.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-26T21:59:09.135883+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}